GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Cyclically Adjusted PB Ratio

Vanda Pharmaceuticals (FRA:VM4) Cyclically Adjusted PB Ratio : 0.81 (As of Jun. 04, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Vanda Pharmaceuticals's current share price is €4.82. Vanda Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €5.93. Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.81.

The historical rank and industry rank for Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:VM4' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.54   Med: 5.35   Max: 14.44
Current: 0.75

During the past years, Vanda Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 14.44. The lowest was 0.54. And the median was 5.35.

FRA:VM4's Cyclically Adjusted PB Ratio is ranked better than
68.75% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs FRA:VM4: 0.75

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €8.600. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.93 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.05 3.85 3.58 1.34 0.65

Vanda Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 1.08 0.68 0.65 0.60

Competitive Comparison of Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.82/5.93
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Vanda Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=8.6/131.7762*131.7762
=8.600

Current CPI (Mar. 2024) = 131.7762.

Vanda Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.019 100.560 0.025
201409 0.024 100.428 0.031
201412 3.144 99.070 4.182
201503 3.371 99.621 4.459
201506 3.156 100.684 4.131
201509 3.037 100.392 3.986
201512 2.852 99.792 3.766
201603 2.562 100.470 3.360
201606 2.501 101.688 3.241
201609 2.620 101.861 3.389
201612 2.830 101.863 3.661
201703 2.690 102.862 3.446
201706 2.608 103.349 3.325
201709 2.437 104.136 3.084
201712 2.471 104.011 3.131
201803 3.753 105.290 4.697
201806 4.107 106.317 5.090
201809 4.275 106.507 5.289
201812 4.613 105.998 5.735
201903 4.652 107.251 5.716
201906 4.930 108.070 6.011
201909 6.825 108.329 8.302
201912 6.907 108.420 8.395
202003 6.961 108.902 8.423
202006 7.016 108.767 8.500
202009 6.839 109.815 8.207
202012 6.791 109.897 8.143
202103 7.070 111.754 8.337
202106 7.180 114.631 8.254
202109 7.527 115.734 8.570
202112 7.994 117.630 8.955
202203 8.071 121.301 8.768
202206 8.507 125.017 8.967
202209 9.204 125.227 9.685
202212 8.764 125.222 9.223
202303 8.711 127.348 9.014
202306 8.667 128.729 8.872
202309 8.846 129.860 8.977
202312 8.685 129.419 8.843
202403 8.600 131.776 8.600

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vanda Pharmaceuticals  (FRA:VM4) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vanda Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (FRA:VM4) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines